Lytix Biopharma enters into an exclusive license agreement with the Arctic University of Norway for a class of new drug candidates - and forms a strategic partnership with the US-based Aurelius Biotherapeutics
Lytix Biopharma AS, in collaboration with a research team at the Arctic University of Norway (UiT), has developed a new group of promising drug candidates, which can combat cancer cells through stimulating the body’s own immune cells.
Lytix Biopharma AS has entered into an exclusive license agreement with UiT – the Arctic University of Norway, facilitated by the technology transfer office Norinnova AS. The drug candidates licensed have been developed in a collaboration between UiT – the Arctic University of Norway and Lytix Biopharma, partly funded by the Norwegian Research Council and the Norwegian Cancer Society.
- Over the past year, we have achieved several key milestones with our most advanced drug candidate, LTX-315, and have successfully confirmed the unique potential of our technology platform. Through one of the joint projects with the scientific expertise at UiT, a set of new promising molecules have been discovered. This exclusive license agreement expands our overall product portfolio, which further demonstrates the robustness of our approach to this segment, says CEO Øystein Rekdal at Lytix Biopharma.
A combined team from UiT – the Arctic University of Norway, Norce, Oslo University Hospital and Institute Gustave Roussy in Paris have contributed to the project. The agreement grants Lytix Biopharma all rights to further develop and commercialize this new class of compounds. In line with the company’s existing portfolio, this new class activates the immune system to combat the cancer cells.
- One of the compounds seems especially promising and suitable for the veterinary medicine market. We have formed a strategic partnership with the US based specialist veterinary medicine company Aurelius Biotherapeutics to expedite the progression of this compound, says Rekdal in Lytix Biopharma.
Aurelius Biotherapeutics now initiates further studies on one of the compounds, to validate the initial data, and to refine its target product profile. Aurelius is currently also developing their own lead candidate, ACT-1, granted by the USDA-Center for Veterinary Biologics, which now will be combined with the Lytix drug candidate.
- Our partnership with Lytix Biopharma is a big step forward in the treatment of lymphoma in our canine companions. Lytix Biopharma is the leader in developing oncolytic molecules and their expertise in this field is invaluable to this therapy. Together, we will combine the oncolytic properties of the peptide molecules with the immunotherapy of adoptive T cells, to fill the unmet goal of long-term survival in canine lymphoma. Our goal is to move the combination therapy forward to develop a first in class therapy for canine lymphoma, says Theresa Westfall, CEO at Aurelius Biotherapeutics.
About Aurelius Biotherapeutics Inc
Aurelius Biotherapeutics was founded to address unmet needs in immuno-oncology therapies for cancer in canine companions. Aurelius is currently developing their own lead candidate, ACT-1, granted by the USDA-Center for Veterinary Biologics under a conditional permit for experimental use. Aurelius goal is to provide long term survival that bypasses lengthy chemotherapeutics regimens and improves the quality of life. Aurelius consist of a team of veterinarians and scientists are committed to discovering, responding, and changing the way cancer is treated.